HEALTH● LOWJul 24 · Jul 24, 2026, 7:20 PM
Outlook gains approval for ophthalmic bevacizumab for wet AMD
Seeking Alpha Tech
Outlook has gained approval for ophthalmic bevacizumab for the treatment of wet Age-related Macular Degeneration (AMD). This signifies a new therapeutic option for the condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoEpilepsy pushed under with years - long treatment waitwesternadvocate.com.au · AustraliaHEALTH1h agoAlert for the "Cicada virus" which is already in Argentina: the curious origin of its name and the risk of contagionClarínHEALTH1h agoLassa fever: NCDC identifies preparedness gaps, unveils readiness plan ahead of peak seasonPremium TimesHEALTH2h agoExperimental AstraZeneca Drug Reduces COPD Flare-Ups in Late-Stage TrialsHuman Progress